| P50 | author | Justine Bacchetta | Q51382492 |
| P2093 | author name string | Justine Bacchetta | |
| P2860 | cites work | Fibroblast growth factor 23 inhibits extrarenal synthesis of 1,25-dihydroxyvitamin D in human monocytes | Q24604832 |
| | FGF23 promotes renal calcium reabsorption through the TRPV5 channel | Q28509196 |
| | Presence of valvular calcification predicts the response to cinacalcet: data from the ADVANCE study | Q30682951 |
| | Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis | Q33932297 |
| | Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease | Q34027316 |
| | FGF23 induces left ventricular hypertrophy | Q34028891 |
| | Evaluation of hypophosphatemia: lessons from patients with genetic disorders. | Q35073296 |
| | Soluble Klotho Protects against Uremic Cardiomyopathy Independently of Fibroblast Growth Factor 23 and Phosphate | Q35550609 |
| | Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. | Q35558693 |
| | The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial | Q35576108 |
| | Treatment of established left ventricular hypertrophy with fibroblast growth factor receptor blockade in an animal model of CKD. | Q35588217 |
| | Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial | Q35658608 |
| | FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality | Q36068303 |
| | Klotho Protects Against Indoxyl Sulphate-Induced Myocardial Hypertrophy | Q36104796 |
| | Low Vitamin D and High Fibroblast Growth Factor 23 Serum Levels Associate with Infectious and Cardiac Deaths in the HEMO Study | Q36417886 |
| | Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease | Q37440758 |
| | Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia | Q37679946 |
| | Forging forward with 10 burning questions on FGF23 in kidney disease | Q37761239 |
| | The role of bone in CKD-mediated mineral and vascular disease | Q38244314 |
| | New insights into the FGF23-Klotho axis. | Q38286695 |
| | Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial | Q38410120 |
| | Biphasic Effects of Vitamin D and FGF23 on Human Osteoclast Biology. | Q40926098 |
| | Assessing the treatment effect in a randomized controlled trial with extensive non-adherence: the EVOLVE trial | Q41103027 |
| | FGF23 regulates renal sodium handling and blood pressure | Q42952198 |
| | Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis | Q44871721 |
| | Fibroblast Growth Factor 23 (FGF23) Predicts Progression of Chronic Kidney Disease: The Mild to Moderate Kidney Disease (MMKD) Study | Q59575076 |
| | FGF23: more a matter of the heart than of the vessels? | Q87630533 |
| P921 | main subject | chronic renal insufficiency | Q736715 |
| P304 | page(s) | 770 | |
| P577 | publication date | 2016-01-06 | |
| P1433 | published in | BoneKEy reports | Q27724456 |
| P1476 | title | FGF23 in chronic kidney disease: are we lost in translation? | |
| P478 | volume | 5 | |